Literature DB >> 16493513

Tissue distribution of radioiodinated FAUC113: assessment of a pyrazolo(1,5-a) pyridine based dopamine D4 receptor radioligand candidate.

O Prante1, C Hocke, S Löber, H Hübner, P Gmeiner, T Kuwert.   

Abstract

AIM: Disturbances of the D4 receptor subtype have been implicated in the genesis of a broad range of psychiatric disorders. In order to assess the suitability of a radioiodinated analogue of the D4-selective ligand FAUC 113 for tracer studies in vivo, we investigated the in-vivo stability, biodistribution and brain-uptake of 7-(131)I-FAUC 113 in Sprague-Dawley rats.
METHODS: Radiolabelling was carried out with high radiochemical yield and specific activity. After intravenous injection, blood and tissue samples, taken at designated time intervals, were collected for analysis. Analyses of metabolites were performed by radio-hplc and radio-tlc. For in-vivo evaluation, sagittal cryo-sections of the rat brain were investigated by in-vitro and ex-vivo autoradiography on a mu-Imager system.
RESULTS: 7-(131)I-FAUC 113 was rapidly cleared from blood. Highest uptake was observed in kidney (0.603 +/- 0.047% ID/g, n = 4) and liver (0.357 +/- 0.070% ID/g, n = 4) at 10 min p.i.; 7-(131)I-FAUC 113 displayed rapid uptake (0.21-0.26% ID/g) and fast clearance in various brain regions consistent with the determined logP-value of 2.36 +/- 0.15 (n = 4). In-vivo stability of 7-(131)I-FAUC 113 was confirmed in the frontal cortex (>95%). Ex-vivo autoradiography revealed a frontal cortex-to-cerebellum ratio of 1.57 +/- 0.13 at 10 min p.i. (n = 6). Coinjection with L-750667 could not suppress any putative specific binding of 7-(131)I-FAUC 113. In-vitro autoradiography using authentic 7-iodo-FAUC 113 or L-750667 failed to cause significant displacement of the radioligand.
CONCLUSIONS: Radioiodinated FAUC 113 does not allow imaging of D4 receptors in the rat brain in vivo nor in vitro. Further work should aim at the development of selective dopamine D4 radioligands with improved tracer characteristics, such as receptor affinity and subtype selectivity, specific activity or blood-brain barrier permeability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16493513     DOI: 10.1267/nukl06010041

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  4 in total

1.  Synthesis and biological evaluation of PET tracers designed for imaging of calcium activated potassium channel 3.1 (KCa3.1) channels in vivo.

Authors:  Kathrin Brömmel; Christian Paul Konken; Frederik Börgel; Henry Obeng-Darko; Sonja Schelhaas; Etmar Bulk; Thomas Budde; Albrecht Schwab; Michael Schäfers; Bernhard Wünsch
Journal:  RSC Adv       Date:  2021-09-10       Impact factor: 4.036

2.  Towards Optimized Bioavailability of 99mTc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity.

Authors:  Lisa Honold; Melanie Austrup; Andreas Faust; Christian Paul Konken; Katrin Schwegmann; Bastian Zinnhardt; Constantin Gabriel Daniliuc; Günter Haufe; Michael Schäfers; Klaus Kopka; Sven Hermann
Journal:  Mol Imaging Biol       Date:  2021-11-08       Impact factor: 3.484

3.  Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline-Based κ-Opioid Receptor (KOR) Agonists Designed for PET Studies.

Authors:  Giovanni Tangherlini; Frederik Börgel; Dirk Schepmann; Samuel Slocum; Tao Che; Stefan Wagner; Katrin Schwegmann; Sven Hermann; Nadine Mykicki; Karin Loser; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2020-09-01       Impact factor: 3.466

4.  Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on γ-fluorinated α-sulfonylaminohydroxamic acid.

Authors:  Verena Hugenberg; Malte Behrends; Stefan Wagner; Sven Hermann; Michael Schäfers; Hartmuth C Kolb; Katrin Szardenings; Joseph C Walsh; Luis F Gomez; Klaus Kopka; Günter Haufe
Journal:  EJNMMI Radiopharm Chem       Date:  2018-07-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.